CEL-SCI Corporation (CVM)
Largest Insider Buys in Sector
CVM Stock Price History Chart
CVM Stock Performance
About CEL-SCI Corporation
CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and …
Insider Activity of CEL-SCI Corporation
Over the last 12 months, insiders at CEL-SCI Corporation have bought $80,620 and sold $0 worth of CEL-SCI Corporation stock.
On average, over the past 5 years, insiders at CEL-SCI Corporation have bought $204,078 and sold $269,917 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Watson Robert Eugene (director) — $55,600. KERSTEN GEERT R (Chief Executive Officer) — $41,700. PRICHEP PATRICIA B (Senior Vice President) — $11,120.
The last purchase of 30,000 shares for transaction amount of $41,700 was made by KERSTEN GEERT R (Chief Executive Officer) on 2024‑05‑08.
List of Insider Buy and Sell Transactions, CEL-SCI Corporation
| 2024-05-08 | Chief Executive Officer | 30,000 0.0556% | $1.39 | $41,700 | -20.14% | |||
| 2024-05-08 | Senior Vice President | 8,000 0.0148% | $1.39 | $11,120 | -20.14% | |||
| 2024-05-08 | director | 20,000 0.0371% | $1.39 | $27,800 | -20.14% | |||
| 2021-10-19 | Sale | Chief Scientific Officer | 15,000 0.0345% | $11.25 | $168,750 | -63.02% | ||
| 2021-07-06 | Chief Executive Officer | 25,000 0.0615% | $8.00 | $200,000 | -9.69% | |||
| 2021-07-06 | director | 1,250 0.0031% | $8.00 | $10,000 | -9.69% | |||
| 2021-07-06 | director | 1,250 0.0031% | $8.00 | $10,000 | -9.69% | |||
| 2021-06-28 | director | 3,000 0.0068% | $12.66 | $37,971 | -44.12% | |||
| 2021-04-22 | Sale | Senior Vice President | 10,000 0.0244% | $24.38 | $243,793 | -62.09% | ||
| 2020-12-11 | director | 100 0.0003% | $14.24 | $1,424 | -8.02% | |||
| 2020-11-18 | director | 800 0.0021% | $11.77 | $9,416 | +16.45% | |||
| 2020-11-18 | director | 800 0.0021% | $11.77 | $9,416 | +16.45% | |||
| 2020-11-17 | director | 800 0.0021% | $11.68 | $9,343 | +16.15% | |||
| 2020-11-13 | Sale | Senior Vice President | 10,000 0.026% | $12.73 | $127,290 | +6.47% | ||
| 2020-11-04 | director | 3,000 0.0076% | $11.35 | $34,060 | +16.45% | |||
| 2020-02-26 | Chief Executive Officer | 4,617 0.0128% | $10.83 | $50,002 | +23.45% | |||
| 2020-02-26 | Senior Vice President | 3,694 0.0051% | $5.42 | $20,003 | +23.45% | |||
| 2020-02-26 | Senior Vice President | 923 0.0026% | $10.83 | $9,996 | +23.45% | |||
| 2020-02-26 | director | 923 0.0026% | $10.83 | $9,996 | +23.45% | |||
| 2020-02-26 | director | 923 0.0026% | $10.83 | $9,996 | +23.45% |
Insider Historical Profitability
| KERSTEN GEERT R | Chief Executive Officer | 1195309 1.8733% | $0.69 | 30 | 0 | +9.11% |
| PRICHEP PATRICIA B | Senior Vice President | 232326 0.3641% | $0.69 | 7 | 0 | +0.31% |
| Watson Robert Eugene | director | 24431 0.0383% | $0.69 | 4 | 0 | +10.07% |
| ZIMMERMAN DANIEL H | Senior Vice President | 114387 0.1793% | $0.69 | 5 | 3 | +23.45% |
| TALOR EYAL | Chief Scientific Officer | 104899 0.1644% | $0.69 | 4 | 16 |
Institutional Investor Ownership
| The Vanguard Group | $4.19M | 4.05 | 2.19M | +5.47% | +$217,172.75 | <0.0001 | |
| Cvi Holdings Llc | $1.68M | 1.62 | 878,767 | New | +$1.68M | 1.75 | |
| BlackRock | $1.46M | 1.41 | 763,443 | +1.14% | +$16,498.58 | <0.0001 | |
| Susquehanna International Group | $1.28M | 1.24 | 668,989 | +72.28% | +$536,091.16 | <0.01 | |
| Geode Capital Management | $887,256.00 | 0.86 | 464,409 | -2.92% | -$26,726.06 | <0.0001 |